NCT00952614

A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion

A Pilot Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Glenn Jaffe · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether a fluocinolone sustained drug delivery implant is effective in the treatment of central retinal vein occlusion that has caused persistent macular edema and decreased visual acuity.

Detailed description

Currently there is limited treatment for macular edema and vision loss due to central retinal vein occlusion. Case reports have shown some benefit of intravitreal steroid injections in improving vision and reducing macular edema in eyes with retinal vein occlusions. Recently, a sustained drug release steroid implant has been investigated and FDA approved to treat macular edema in patients with non-infectious uveitis, eye inflammation. This implant is placed through an incision in the eye wall and is designed to deliver a steroid, fluocinolone acetonide, for up to three years. In animal studies there was no detectable steroid seen in the blood stream. This pilot trial will recruit individuals who have had a central retinal vein occlusion in at least one eye. If the macular edema and vision improves with an initial intravitreal injection, the eye will be considered to receive the sustained drug release device. The dosage of fluocinolone acetonide used is 0.59 mg.

Conditions

• Central Retinal Vein Occlusion

Interventions

Type	Name	Description
DEVICE	fluocinolone acetonide (Retisert Implant, Bausch and Lomb)	sustained release device consisting of 0.59 mg of fluocinolone acetonide

Timeline

• Start date: 2002-10-01
• Primary completion: 2009-05-01
• Completion: 2009-05-01
• First posted: 2009-08-06
• Last updated: 2014-08-06
• Results posted: 2014-06-30

Locations

1 site across 1 country: United States